Impact of Pyrazinamide Regimen on Serum Uric Acid Levels in TB Patients by Mathan Kumar, R
IMPACT OF PYRAZINAMIDE REGIMEN ON 
SERUM URIC ACID LEVELS IN TB PATIENTS
DISSERTATION SUBMITTED FOR
THE DEGREE OF DOCTOR OF MEDICINE
BRANCH I GENERAL MEDICINE
MARCH – 2009
THE TAMILNADU Dr. M.G.R. MEDICAL UNIVERSITY
CHENNAI – TAMILNADU
CERTIFICATE
This is to certify that the dissertation titled “Impact of Pyrazinamide regimen on Serum Uric 
Acid levels in TB patients” submitted by                            Dr.R. Mathan kumar to the Faculty of 
Medicine, The Tamilnadu Dr. M.G.R. Medical University, Chennai in partial fulfillment of the 
requirement for the award of M.D. Degree (Medicine) is a bonafide research work carried out by him 
under our direct supervision and guidance.
Dr. Moses K. Daniel M.D.                Dr. Iyyappan  M.D.
Professor of Medicine,             Professor and Head of the Department
Department of Medicine,  Department of Medicine,
Madurai Medical College,  Madurai Medical College, 
Madurai.  Madurai.
       
DECLARATION
I.  Dr.  Mathan  kumar, solemnly  declare  that  the  dissertation  titled  “Impact  of  
Pyrazinamide regimen on serum uric acid levels in TB patients” has been prepared by me.
This is submitted to the Tamilnadu Dr. M.G.R. Medical University, Chennai in partial  
fulfillment of the rules and regulations for the M.D. Degree Examination in General Medicine.
Place :  Madurai
Date :   Dr. Mathan kumar
ACKNOWLEDGEMENT
I thank the DEAN of Madurai Medical College and Government Rajaji 
Hospital for extending her support to conduct this study.
I am grateful to the Professor and Head of the Department of Medicine 
Dr. AYYAPPAN M.D., for helping to select and allowing to do this topic. I 
am greatly  indebted  to  Dr.  MOSES.  K.  DANIEL M.D.,  for  her  excellent 
support and valuable guidance through the study period.
I  am  extremely  thankful  to  our  Throacic  Medicine  Professor 
Dr.  RAMESH  MD.,  (Resp.Med.)  and  Assistant  Professor 
Dr. VIVEKANANDAN DTCD; MD for their generous help and guidance.
I  extend my thanks  to  my assistant  Professor  Dr.  K.  SENTHIL M.D., 
Dr. DAVID PRADEEPKUMAR M.D.,  Dr. GANESHBABU M.D., and for 
their kind assistance, encouragement and guidance they gave me.
I am thankful to all my colleagues who helped me in this endeavor.
Last but not the least. I am indebted to the patients who became part of 
this study. 
4
CONTENTS
S.N
o.
Contents Page No.
1. Introduction 1
2. Aim of the study 2
3. Review of Literature 3
4. Mechanism of Hyperuricemia and Arthralgia 13
5. Materials and Methods 18
6. Study Design 21
7.      Results of the study 25
8.      Discussion 44
9.      Conclusion 50
     Appendix
     Bibliography
     Master Chart
5
INTRODUCTION
Recently  increased  importance  is  given  to  chemotheraphy  in  the 
treatment of tuberculosis. This has given great relief to the patients suffering 
from this disease.
But at the same time, the multidose therapy has resulted in enhanced 
toxity and other drug reactions. Hence a better understanding of the scientific 
principles of the phenomenon of drug reaction through various studies has 
become essential to bring better results in treatment of tuberculosis. 
Pyrazinamide  was  formerly  a  reserve  regimen  drug  used  for  the 
treatment  of  patients  who  had  failed  with  primary  chemotherapy.  Today, 
Pyrazinamide  is  at  the  fore  front  of  the  chemotherapeutic  armamentorium 
along  with  Rifampicin  and  INH  as  one  of  the  pillars  of  Short  Course 
Chemotheraphy. A not infrequent reaction to pyrazinamide is hyperuricemia 
and arthralgia (Hong Kong / BMRC study 1976, Horsfall 1979, Sharma and 
Jain, Lung India 1983) which is probably due to inhibition of renal excretion 
of  uric  acid.  However  the  exact  mechanism  of  arthralgia  is  yet  to  be 
established on firmer grounds. 
The  current  study  was  undertaken  to  determine  the  incidence  of 
hyperuricemia and arthralgia in regimens containing pyrazinamide. 
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AIM OF THE STUDY
1. To  study  incidence  of  hyperuricemia  in  patients  receiving,  anti 
tuberculosis therapy containing pyrazinamide.
2. To evaluate the incidence arthralgia in the above regimen.
3. To  study  the  relationship  between  age,  sex  and  drug  regimen  and 
incidence of hyperuricemia and arthralgia.  
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REVIEW OF LITERATURE
Metabolism and Pathological conditions of uric Acid 
The end product of purine metabolism in humans is urate, In most of 
the mammals it is further broken down into the soluble compound, allantoin, 
and it is the poor solubility of urates which makes man prone to clinical gout 
and renal damage by urate. The purines adenine and guanine are constituents 
of both types of nucleic acid (DNA and RNA). The purines used by the body 
for nucleic acid synthesis  may be derived from two sources.
1. Breakdown of ingested nucleic acids (mainly in meat).  
2. May be synthesised in the body from small molecules dnovo.
Synthesis of Purines
There are four steps in which synthesis of purine can be considered.
In the first step of purine synthesis : condensation of pyrophosphate 
with phosphoribose to form phosphoribosyl pyrophosphate (PRPP).
In the second step, amino group of glutamine is incorporated into the 
ribose  phosphate  molecule  and  pyrophosphate  is  released. 
Amidiphosphoribosyl tranferase catalyses this rate-limiting or controlling step 
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in purine synthesis. It is subject to feedback inhibition from increased levels 
of purine nucleotides. Thus the rate of synthesis is slowed when its products 
increase. This step may be at fault in primary gout.
In the Third Step, the glycine molecule is added to phosphoribosylamine.
After  many  complex  steps  purine  ribonucleotides  (purine  ribose 
phosphates)  are  formed and as  has  already been stated,  the  level  of  these 
controls (Second step).  Ribose phosphate is split  off,  therapy releasing the 
purines. 
Fate of Purines
Purines synthesised in the body, those derived from the diet and those 
liberated by endogenous breakdown of nucleic acids may follow one of the 
two pathways : they may be synthesised into new nucleic acid; or be oxidized 
to urate.
Formation of urate from purines
As shown in the figure, some of adenine is oxidized to hypoxanthine, 
which  is  further  oxidized  to  xanthine.  Guanine  can  also  form  xanthine. 
Xanthine,  in  turn  is  oxidized  to  form  urate.  The  oxidation  of  both 
hypoxanthine and xanthine is catalyzed by the liver enzyme xanthine oxidase. 
Thus  the  formation  of  urate  from  purines  depends  on  xanthine  oxidase 
activity, a fact of importance in the treatment of gout.
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Reutilization of purines
Some  xanthine,  hypoxanthine  and  guanine  can  be  resynthesised  to 
purine  nucleotides  by  pathways  involving,  amongst  other  enzymes, 
Hypoxanthine – Guanine Phosphoribosyl Transferase (HGPRT) and Adenine 
Phosphoribosyl Transferase (APRT).
Excretion of urate
75 percent of the urate leaving the body is excreted in the urine and 25 
percent  passes  into  the  intestine,  where  it  is  broken  down  by  intestinal 
bacterial (uricolysis). The urate filtered at the renal glomerulus is probably 
completely reabsorbed in the tubules and the urinary urate is derived from 
active tubular secretion : urinary excretion may be enhanced by various drugs 
used in the treatment of gout.
Renal excretion of urate is inhibited by such organic acids as lactic and 
oxacids.
Uric  Acid  is  the  final  breakdown product  of  purine  degradation  in 
humans.  Serum urate concentrations vary with age and sex. Most children 
have serum urate concentrations of 3 – 4mg/dl. Levels begin to rise at puberty 
in males but remain low in females until menopause. Although the cause of 
this sex variation is unknown, it is in part due to higher functional excretion 
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of urate in female and is attributable to hormonal influence, Mean serum urate 
values for men and premenopausal women are 6.8 and 6.8 mg/dl respectively. 
After  menopause,  values  for  women  approximate  those  of  men.  Adult 
concentrations  rise  steadily  over  the  time,  vary  with  height,  body  weight, 
blood pressure, renal function and alcohol intake. 
Causes of hyperuricemia
It  could  be  due  to  increased  production  of  uric  acid  /  decreased 
excretion of Uric Acid or a combination of both.
CLASSIFICATION OF HYPERURICEMIA
Urate over Production
Primary idiopathic HPRT deficiency
PRPP synthetase over activity
Hemolytic proceses
Lymphoproliferative diseases
Polycythemia vera
Psoriasis
Paget’s disease
Glycogenosis III,
Glycogenosis V,
and Glycogenosis VII,
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Rhabdomyolysis
Exercise
Alcohol
Obesity
Purine-rich diet 
Decreased Uric Acid Excretion
Primary idiopathic
Renal insufficiency
Polycystic kidney disease
Diabetes insipidus
Hypertension
Acidosis
Lactic acidosis
Diabetic Ketoacidosis
Starvation ketosis
Berylliosis
Sarcoidosis
Lead intoxication
Hyperparathyroidism
Hypothyroidism
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Toxemia of pregnancy
Bartters Syndrome
Down syndrome
Drug ingestion
Salicylates (> 2 g/d)
Decreased Uric Acid Excretion
Diuretics
Alcohol
Levodopa
Ethambutol
Pyrazinamide
Cyclosporine
Combined Mechanism
Glucose – 6 phosphatase Deficiency
Fructose – 1 – phosphate – aldolase deficiency
Alcohol
Shock
Complications of hyperuricemia
Asymptomatic  hyperuricemia  can  lead  to  Acute  Gouty  arthritis  and 
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chronic  or  tophaceous gout.  Nephrolithiasis  can occur before or  after  first 
attack of gouty arthritis. 
Gout
The term is used to describe a number of disorders in which crystals of 
monosodium urate monohydrate derived from hyperuricemic body fluids give rise to 
inflammatory arthritis, tenosynovitis, bursitis or cellulitis, tophaceous deposits, 
urolithiasis and renal disease. Hyperuricemia is a necessary but not a sufficient pre 
requisite for clinical manifestation of gout.
Clinical Features
Acute Gout
The metatarsophalangeal joint of great toe is the site of first attack of 
acute gouty arthritis in 70% of patients; the wrist, the ankle, the knee, the 
small  joints  of the  feet  and hand the  elbow follow in decreasing order  of 
frequency.  The  affected  joint  is  hot,  red  and  swollen  and  excruciatingly 
painful  and  tender.  Recurrent  acute  attacks  are  followed  by  progressive 
destruction  of  cartilage  and  bone  erosion  –  chronic  gout.  The  other 
manifestations include urate urolithiasis and chronic urate nephropathy.
Interval (or) Intercritical Gout
It  describes  the  period  between  attacks  of  acute  arthritis  when  the 
individual has no joint complaints. 
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Chronic (or) Tophaceous Gout
Characterised by persistent polyarticular low grade pain with acute or 
sub acute inflammation. During this stage, tophi become apparent on physical 
examination. 
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MECHANISM OF HYPERURICEMIA 
AND ARTHRALGIA
Mechanism of Action of Pyrazinamide
Pyrazinamide  is  a  synthetic  analogue  of  Nicotinamide  –  Pyrazinoic 
acid  amide.  The  exact  mechanism  of  the  antimycobacterial  action  of 
Pyrazinamide  (PZA)  is  not  completely  known.  Early  experimental  studies 
showed  that  the  activity  of  PZA varied  with  the  degree  of  acidity  of  the 
environment.
PZA is believed to act specifically on intracellular organism partially 
inhibited by the acid condition of the macrophages. The current hypothesis 
regarding the antituberculosis action of PZA is as follows: First, in the acidic 
environment  of  the  host  phago lysosomes,  the  tubercle  bacilli  produce  an 
enzyme,  pyrazinamidase,  that  converts  PZA to  pyrazinoic  acid  (POA).  In 
vitro,  POA  is  inhibitory  to  tubercle  bacilli,  the  degree  of  inhibition 
proportional to its concentration and a decrease in pH. POA unlike its parent 
compound PZA, does not seem to penetrate the membrane of the macrophage 
readily,  Second,  the  POA  that  is  produced  accumulates  in  the 
phagolysosomes, thereby lowering the microenvironmental pH sufficiently to 
be toxic to tubercle bacilli.
18
NN
C
O
N H 2
S T R U C T U R E  O F  P Y R A Z I N A M I D E
19
Third, at the same time, mycobacterial metabolism produces ammonia 
which can increase intracellular pH, and neutralizes the acidity of POA to a 
certain extent, thereby decreasing the effectiveness of PZA.
MECHANISM OF PYRAZINAMIDE
INDUCED HYPERURICEMIA & ARTHRALGIA
Pyrazinamide
Xanthine Oxidase
Pyrazinonic Acid In active
metabolites
Competes with uric acid
for tubular secretion
Inhibits renal tubule
Secretion of uric acid
Hyperuricemia
Deposition of monosodium
urate crystals in joints Arthralgia
Crowle study suggested that although low pH is probably associated 
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with the effectiveness of PZA. Crowle study suggested that although low pH 
is probably more a consequence of bacterial more a consequence of bacterial 
than of host cell activity. The minimal inhibitory concentration (MIC) of PZA 
for Mycobacterium tuberculosis on 7H 10 agar medium at pH 5.5 was shown 
to be 18 micro gram/ml. PZA susceptibility of a given strain of tuberculosis 
correlates with the pyrazinamidase activity. Susceptible strains have a high 
level  of  pyrazinamidase  activity  and  resistant  strains  a  reduced  level  of 
activity. This is the principle behind the in vitro PZA susceptibility testing 
currently used.
PZA is rapidly absorbed from the gastrointestinal tract. No evidence of 
the  drug  is  detectable  in  the  patient’s  faeces,  which  suggests  that  the 
absorption is virtually complete. The drug is distributed widely in the body. It 
is found in the cerebrospinal fluid in the same concentration as that in the 
serum of patients with tuberculous meningits. The serum half-life of PZA is 9 
to 10 hours. The drug is excreated in the urine, 40 percent as pyrazinoic acid 
and 3 percent as unchanged PZA.
Mechanism of Hyperuricemia and Arthralgia
The exact mechanism of pyrazinamide induced hyperuricemia remains 
to be elucidated. The sequence of events in the causation of hyperuricemia 
and arthralgia in patients on pyrazinamide is depicted above.
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Pyrazinamide is converted to pyrazinoic acid by hepatic deaminidase 
which is  further hydroxylated to 5 – hydroxy pyrazinoic acid by xanthine 
oxidase.  Pyrazinoic  acid is  supposed to  be  the  active  metabolism in man. 
Urate,  the  end  product  of  purine  metabolism  is  excreted  by  glomerular 
filtration and subsequent reabsorption in proximal tubule. The serum uric acid 
concentration is greatly dependent upon the rate of renal clearance of uric acid 
which is dependent upon the distal tubular secretion of uric acid that is almost 
totally  inhibited  by  pyrazinoic  acid.  Pyrazinoic  acid  may  also  increase 
proximal  reabsorption  of  filtered  uric  acid.  As  a  result,  serum  uric  acid 
concentration increases leading to deposition of monosodium urate crystals in 
the  joints.  This  being the  probable  mechanism of  action  of  pyrazinamide, 
allopurinol is not advised in the management of arthralgia since it  being a 
xanthine oxidase inhibitor will increase the concentration of pyrazinoic acid. 
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MATERIALS AND METHODS
This study was carried out in patients attending the Thoracic Medicine, 
clinic, Govt. Rajaji Hospital Madurai from January 2008 to September 2008. 
Hundred and Fifty patients diagnosed to have Tuberculosis, both pulmonary 
and  extrapulmonary  were  taken  up  for  the  study.  This  included  sputum 
positive and sputum negative pulmonary tuberculosis patients. Patients with 
pleural effusion and lymphadenopathy of tuberculous etiology were also part 
of the study. Serum Uric Acid levels were estimated for all the patients by 
phosphotungstate method before treatment and at the end two months.
Procedure for estimating serum Uric Acid by Phosphotungstate method
Principle : Uric Acid, in alkaline medium reduces phosphotungstic acid 
into  “  Tungsten  Blue”,  a  blue  coloured  complex,  which  is  measured 
colorimetrically.
Preparation of standard solution
50ml of distilled water is taken and 0.5ml of stock Uric Acid standard 
is added and mixed will. All other reagents are ready for use 3 ml is taken 
from this and to this 1 ml of sodium carbonate and 1 ml of phosphotungstate 
are added. After waiting for 15 minutes, reading is noted on the colorimeter. 
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Deproteinisation of the sample : Step A
I ml of serum is taken in a centrifuge tube, 8 ml of distilled water is 
added followed by 0.5ml of 2/3 N sulphuric acid and 0.5 ml of 10% W/v 
sodium tungstate wait for ten minutes. Then it is centrifuged for ten minutes 
till white precipitate completely separates. 
Colour Development : Step B
3ml of the above supernatant liquid is taken and to this 1 ml of 14% 
W/v sodium carbonate and 1 ml of phosphotungstate are added, mixed well 
and  kept  for  fifteen  minutes  in  dark.  The  reading  is  then  taken 
colorimetrically.
Calculation of serum Uric Acid in mg/100 ml
= O.D test – O.D blank 
x 10
   O.D std – O.D. Blank 
Normal Values
Men : 25 – 7 mg/ 100 ml
Women : 1.5 – 6 mg/100 ml
1. Serum should be free from any hemolysis.
2. Use clean and dry glassware.
3. Bring all the solution to room temperature before use.
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4. Prepare a blank and standard for each series of determinations.
5. Mark the test tubes properly as Blank (B), Standard (S) and Test (T) 
before proceeding for estimation.
25
STUDY DESIGN
Criteria for Inclusion
Patients  aged  12  years  and  above  of  both  sexes  who  fall  into  the 
following category were taken up for the study.
a. Newly  diagnosed  cases  of  pulmonary  tuberculosis  as  evidenced  by 
sputum smear for AFB positivity and those who were smear negative 
but had radiological lesion.
b. Cases  of  extrapulmonary  Tuberculosis  as  evidenced  by  appropriate 
investigations also were a part of the study.
Criteria for exclusion:
Patients who were known to have
1. History of prior arthropathy
2. Prior ATT
3. Hypertension
4. Renal insufficiency
5. Any other medication
6. H/O chronic alcohol intake.
were excluded from the study.
The patients were divided into three groups depending on the type of 
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treatment they received. All sputum positive patients received IN, Rifampicin, 
Pyrazinamide and Ethambutol on a daily basis for 2 months followed by INH 
and rifampicin thrice weekly for 4 months (2HREZ/4H3R3).
Sputum negative patient and those with extrapulmonary tuberculosis 
received INH, Rifampicin, Pyrazinamide daily for two months followed by 
inh and rifampicin twice weekly for 4 months (2 HRZ / 4 H3 R3).
Serum uric  acid  levels  were  estimated  for  all  these  patients  before 
starting treatment and the end of 2 months.
Serum uric acid levels were estimated for all the patients before the 
start of treatment and at the end of 2 months.
The order investigations done were
1. X-ray chest PA view
2. Urine – albumin
Sugar 
27
Revised National Tuberculosis Control Program (RNTCP)
TB treatment TB Patients Intensive 
Phase
Continuation 
Phase
Category I - New smear – Positive
- New smear – Negative
     (extensive parenchymal 
      involvement)
- Extra pulmonary 
     (severe form)
2 HREZ
or
2 HRZS
4 HR
or
6 HE
(if resistance to 
R is suspected)
Category II Smear Positive
- Relapse 
- Failure
- Treatment after default
2 HREZS
+ 
1 HREZ 5 HRE
Category III New smear negative 
(milder form) 
Extra pulmonary 
(milder form)
2 HRZ
4 HR 
(or) 6 
HE 
(if Resistance to 
R is suspected)
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RESULTS
A. CHARACTERISTICS OF CASES STUDIED
Table 1
Age distribution
Age in years
Cases
No. %
Less than 20 10 6.7
20-29 33 22
30-39 27 18
40-49 28 18.7
50-59 28 18.7
60 & above 24 16
Total 150 100
Range
Mean
S.D.
14 – 74 years
41.4 years
15.7 years
Age of the cases included in the study ranged from 14 years to 74 
years. 46.7 % of cases were less than 40 years and 53.3% were above 40 
years.
Mean age of the group was 41.4 years and standard deviation 15.7 
years.
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Table   2
Sex
Sex
Cases
No. %
Males 96 64
Females 54 36
 
Men outnumbered women in the cases studied. 64 % of them were men 
whereas only 36% were women.
Table   3
Weight ( in Kgs)
Weight ( in Kgs)
Cases
No. %
Upto 33 kgs 13 8.7
33 – 50 kgs 65 43.3
> 50 kgs 72 48
Range
Mean
S.D.
25-67 kgs
49.4 kgs
11.3 kgs
Mean weight of the cases studied was 49.4 kgs. The minimum weight was 
20  kgs  and  the  maximum  67  kgs.  Nearly  half  (48%)  of  the  patients 
weighed 50 kgs and more.
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Table   4
Regimen
Regimen 
Cases
No. %
HREZ 80 53.3
HRZ 70 46.7
53.3 % of the patients received HREZ regimen and 46.7% 
received HRZ regimen. 
Table  5
Regularity of treatment
Regimen
Continued Discontinued
No. % No. %
HREZ (80) 66 82.5 14 17.5
HRZ (70) 58 82.9 12 17.1
Total 124 82.7 26 17.3
Out of the 80 cases receiving HREZ regimen, 14 cases discontinued 
treatment (17.5). Among the 70 cases who were put on HRZ regimen, an 
equal percentage (17.1%) discontinued. Thus a total of 26 patients (17.3) 
have failed to receive the full treatment.
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Table 6
Serum Uric Acid
Serum Uric 
Acid
Range Mean S.D.
Before treatment 1 – 5.7 3.23 1.2
After treatment 3.3 – 12.6 6.8 1.37
Increase 0 – 8.4 3.73 1.5
Serum acid levels of the patients before treatment was  3.23 + 1.2 
and after treatment 6.8 + 1.37.
There was an increase of 3.73 + 1.5 at the end of the two months 
treatment.
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CHANGES IN SERUM URIC ACID LEVELS
3.23
6.8
3.73
0
1
2
3
4
5
6
7
Serum Uric 
Acid
Before
treatment
after
treatment
increase
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Table 7
Age distribution of patients in the two regimen
Age group
Regimen
HREZ HRZ
No. % No. %
Less than 20(10) 4 40 6 60
20-29 (33) 15 45.5 18 54.5
30-39 (27) 17 63 10 37
40-49 (28) 12 42.9 16 57.1
50-59 (28) 19 67.9 9 32.1
60 & above (24) 13 54.2 11 45.8
Total (150) 80 100 70 100
Range
Mean
S.D.
14 – 70 years
42.6 years
15.3 years
14 – 74 years
40.1
16.1
‘p’ 0.2778
Not significant
The mean age of patients receiving HREZ was 42.6 years and those 
receiving  HRZ  was  40.1  years.  The  difference  was  not  statistically 
significant (p > 0.05)
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Table 8
Sex distribution of patients in the two regimen
Sex
Regimen
HREZ HRZ
No. % No. %
Males (96) 51 53.1 45 46.9
Females(54) 29 53.7 25 46.3
Total 80 100 70 100
‘p’ 0.9185
Not significant
The sex composition of the patients receiving the two different types of 
treatment was nearly identical  and there was no statistically  significant 
difference.
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Table 9
Incidence of Hyperuricemeia and Arthralgia in the two regimen
Complication
Yes No
No. % No. %
Hyperuricemeia 74 59.7 50 40.3
Arthralgia 26 21 98 79
* 26 patients discontinued treatment
Out of the 124 cases continuing treatment at the end of 2 months, 74 
(59.7) had hyperuricemeia and 26 (21%) had arthralgia. 
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B. RELATIONSHIP BETWEEN VARIOUS PARAMETERS AND 
INCREASE IN SERUM URIC ACID LEVELS
Table 10
Age and increase in Serum Uric Acid
Age group
Serum Uric Acid
Before 
treatment
After 
treatment
Increase
Mean S.D. Mean S.D Mean S.D.
Less than 20 2.98 1.02 7.35 0.41 4.37 1.33
20-29 3.32 1.25 7.17 0.78 4.02 1.25
30-39 3.24 1.25 7.14 1.08 4.23 1.08
40-49 3.47 1.33 7.01 1.56 3.75 1.81
50-59 3.39 1.2 6.6 1.34 3.3 1.8
60 & above 2.77 0.96 5.67 1.05 2.89 1.19
‘P’ 0.4589
Not significant
0.0001
Significant
0.007
Significant
Before treatment there was no significant difference in serum uric acid 
levels. After the treatment there is decrease in serum uric acid levels and 
the difference is also statistically significant. Similarly there is statistically 
significant relationship between age and increase in serum uric acid levels 
(p = 0.007).The increase is more in the younger age groups.
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Table 11
Sex and increase in Serum Uric Acid
Sex
Serum Uric Acid
Before 
treatment
After 
treatment
Increase
Mean S.D. Mean S.D Mean S.D.
Males 3.41 1.15 6.85 1.39 3.64 1.51
Females 2.92 1.24 6.71 1.34 3.88 1.47
‘p’ 0.0267
Significant
0.8474
Not significant
0.2178
Not significant
There is no statistically significant difference in the serum uric acid 
levels after treatment and increase in serum uric acid levels between males 
and females.
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Table 12
Drug regimen and increase in Serum Uric Acid
Drug regimen
Serum Uric Acid
Before 
treatment
After 
treatment
Increase
Mean S.D. Mean S.D Mean S.D.
HREZ 3.24 1.06 6.99 1.18 3.81 1.58
HRZ 3.23 1.35 6.58 1.53 3.63 1.39
‘P’ 0.612
Not significant
0.1144
Not significant
0.6181
Not significant
There is no significant relationship the serum uric acid levels and the 
drug regimen (‘p’ = 0.612).
.
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C. RELATIONSHIP BETWEEN VARIOUS PARAMETERS AND 
INCIDENCE OF HYPERURICEMEIA
Table 13
Age and incidence of hyperuricemia
Age group
Incidence of hyperuricemia
Yes No
Less than 20(10) 10 100 - -
20-29 (27) 25 92.6 2 7.4
30-39 (23) 19 82.6 4 17.4
40-49 (22) 12 54.5 10 45.5
50-59 (21) 6 28.6 15 71.4
60 & above (21) 2 9.5 19 90.5
Mean
S.D.
32.7 years
12.7 years
53.6 years
12.4 years
‘p’ 0.0001
Significant
As age increases, incidence of hyperuricemia decreases. There exists 
statistically  significant  relationship  between  age  of  the  patient  and 
incidence of hyperuricemia in TB patients. (p = 0.0001).
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Table 14
Sex  and incidence of hyperuricemia
Sex
Incidence of hyperuricemia
Yes No
No % No %
Males (79) 46 58.2 33 41.8
Females(45) 28 62.2 17 37.8
‘p’ 0.8059
Not significant
There  is  no  significant  difference  in  the  incidence  of  hyperuricemia 
among males and females.
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Table 15
Drug regimen  and incidence of hyperuricemia
Drug regimen
Incidence of hyperuricemia
Yes No
No % No %
HREZ (66) 42 63.6 24 36.4
HRZ (58) 32 55.2 26 44.8
‘p’ 0.4382
Not significant
Among the TB patients receiving HREZ and HRZ regimens, there is 
no significant difference in the incidence of hyperuricemia
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D. RELATIONSHIP BETWEEN VARIOUS PARAMETERS AND 
INCIDENCE OF ARTHALGIA
Table 16
Age and incidence of Arthralgia
Age group
Incidence of Arthralgia
Yes No
Less than 20(10) 2 20 8 80
20-29 (27) 7 25.9 20 74.1
30-39 (23) 7 30.4 16 69.6
40-49 (22) 6 27.3 16 72.7
50-59 (21) 1 4.8 20 95.2
60 & above (21) 3 14.3 18 85.7
Mean
S.D.
36.6 years
14.0 years
42.4 years
16.6 years
‘p’ 0.1248
Not significant
Age  of  the  patient  and  incidence  of  arthralgia  are  not  significantly 
related (‘p’ = 0.1248).
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Table 17
Sex  and incidence of Arthralgia
Sex
Incidence of Arthralgia
Yes No
No % No %
Males (79) 14 17.7 65 82.3
Females (55) 12 26.7 33 73.3
‘p’ 0.3435
Not significant
Incidence of arthralgia has got no significant relationship with sex of 
the patient.
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Table 18
Drug regimen  and incidence of Arthralgia
Drug regimen
Incidence of Arthralgia
Yes No
No % No %
HREZ (66) 17 25.8 49 74.2
HRZ (58) 9 15.5 49 84.5
‘p’ 0.2393
Not significant
Drug  regimen  and  arthralgia  do  not  have  statistically  significant 
relationship (‘p’ = 0.2392).
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Table 19
Incidence of hyperuricemia and Arthralgia
Hyperuricemia
Arthralgia
Yes No
No % No %
Yes (74) 20 27 54 73
No (50) 6 12 44 88
‘p’ 0.0732
Incidence of hyperuricemia and arthralgia are not related. (p > 0.05)
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DISCUSSION
The incidence of hyperuricemia and arthralgia observed in the study in 
the pyrazinamide containing regimens were 59.7% and 21% and this result is 
similar to those observed by other workers. The overall incidence of arthralgia 
in the various studies varies from nil (Zierski and Bek 1980) to as high as 
67% has been reported by Sharma et. al. 1980.
Studies from Tuberculosis Research Centre (1983-84), Tripathi et. al. 
1979, Sharma and Jain 1980-83 have speculated on the possible Rifampicin 
group and 66% of the  one hundred and seventy  nine patients  in  the  non-
rifampicin group. The same workers have reported an incidence 24% of three 
hundred and eighty patients  in the Rifampicin group and 46% in the non-
rifampicin group.
Tolerance  of  Pyrazinamide  in  Short  Course  Chemotheraphy  for 
pulmonary tuberculosis  in children (up to 15years).  This  prospective study 
from Department of pediatrics, hospital infantal la paz, Madrid, Spain. (1985-
1995). Study showed increased serum uric acid in 92.2% of the children (total 
of  114  children)  and  significant  fell  again  1  month  after  Pyrazinamide 
stopped. There was no sign of arthralgia.
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Year Worker Hyperuricemia Arthralgia
1981 Sharma et. al. 43% 16%
1983 Sharma et. al. 79% 19%
1978 Iyer & Srinivasan 70% 67%
1961 Vely et. al. 58% 24%
1983 TRC  (Tuberculosis 
Research Centre
66% 46% 
(Non-Rifampicin 
Group)
1983 TRC 69% 24%  (Rifampicin 
group)
1981 Mehotra et. al. 72% 10%
1980 TB  Association  of 
India
70% 13%
1976 Hongkong  TB 
Association / BMRC
59% 7%
1981 Singapore / BMRC 49% 1%
1980 Zierski & Bed 60% 0%
The  role  Rifampicin  in  Pyrazinamide  induced  arthralgia  has  been 
studied at Tuberculosis Research Centre, Chennai.
Renal excretion of uric acid is suppressed by Pyrazinamide being less 
than 40% at five hours. The excretion of uric acid increases thereafter and 
returns to pretreatment values at 24 hours.  The serum concentration shows 
little  or  no change suggesting that  the  serum is  probably  saturated at  this 
concentration and any further  uric acid must be deposited in the  joints  or 
eliminated by uricolysis.
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The  sustained  level  of  uric  acid  increases  at  24  hours  after  drug 
administration despite the urinary excretion returning to pre-treatment levels 
may be due to the dynamic equilibrium between the deposited uric acid and 
the serum uric acid by mobilizing uric acid from tissues and this could be 
responsible for the lack of association between arthralgia and serum uric acid 
concentration. 
The uricosuric effect of rifampicin could be due to the inhibition of 
tubular reabsorption of filtered uric acid at a post-secretary absorptive site, an 
effect similar to uricosuric agents like salicylate and probenecid. Moreover 
Rifampicin is a known inducer of hepatic microsomal enzymes and this could 
mean  a  greater  activity  of  pyrazinamide  deamidase.  In  addition  to  the 
uricosuric effect, rifampicin also increases the renal elimination of pyrazinoic 
acid, which is the major metabolite responsible for the inhibition of secretion 
of uric acid from the distal tubule.
In the present study, the incidence of hyperuricemia and arthralgia with 
pyrazinamide therapy was 59.7% (74 out of 124) and 21% (28 out of 124) 
respectively. The onset of arthralgia was within 15 days of starting therapy in 
the majority of cases. However, none of the patients had to be discontinue 
treatment because of arthralgia. The patients continued the normal activities 
receiving symptomatic treatment with tablet Ibuprufen 400mg three times a 
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day. In this study all the arthralgic patients were hyperuricemic. However only 
one third of hyperuricemics had arthralgia indicating that hyperuricemia and 
arthralgia were not synonymous. In other words, the hyperuricemia associated 
with pyrazinamide was mostly asymptomatic. It was also noticed that there 
was a statistically significant reduction in the incidence of hyperuricemia with 
advancing age.
Further work on this association is indicated. There was no correlation 
between the degree of hyperuricemia and severity  of arthralgia symptoms. 
There was no incidence of acute gout in our study. There was no relationship 
between the dosage of Pyrazinamide and development of hyperuricemia of 
arthralgia.  Hyperuricemia  and  arthralgia  had  no  statistically  significant 
association with sex.
Multiple  joint  involvement  was  seen  in  4  cases.  There  was  no 
involvement of small joints in our study. In contrast to gout, involving small 
joints like toes is usual and simultaneous involvement of two or more joints is 
uncommon (Graham & Scott 1970).
There  is  only  circumstantial  evidence to  implicate  hyperuricemia in 
pyrazinamide arthropathy. As pointed out by Horsfall  et al.,  on account of 
difference in the types of joints involved between pyrazinamide arthropathy 
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and gout it is possible that different mechanisms may be operative in the two 
conditions. 
The detection of arthralgia was purely a subjective phenomenon. No 
leading  questions  were  asked  and  any  spontaneous  complaint  was  noted 
followed by examination of the affected joint. This could depend on various 
factors like patients  willingness  to  be forthcoming with their  problem and 
awareness of the patient. 
In contrast to the weight bearing joint like knee which was involved in 
our study, in the Hongkong / BMRC study the commonly involved joint was 
shoulder (Hors fall et al. 1972).
Finally as far as the incidence of arthralgia is concerned it is unlikely 
that subjective errors in the diagnosis of arthralgia would entirely account for 
the  large  geographical  variation  observed.  Whether  this  is  due  to  genetic, 
nutritional or some other factor remains to be determined. The susceptibility 
to  arthralgia  might  depend  on  factors  like  concentration  of  urate  binding 
protein in individuals.
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CONCLUSION
FROM  THE  STUDY  WE  ARRIVED  AT  THE  FOLLOWING 
CONCLUSIONS.
1. Pyrazinamide therapy is associated with hyperuricemia 
In our study out of 74 out of 124 (59.7%) patients had hyperuricemia. 
Increase in serum uric acid levels has significant relationship with age but not 
with sex and regimen. 
2. Hyperuricemia and arthralgia are not synonymous
In our study out of 124 patients 28 (21%) were only arthraligic, out of 
74 patients with hyperuricemia. Only 20 (27%) had arthralgic. Age, Sex and 
dose of drug not related to arthralgia.
3. Pyrazinamide induced hyperuricemia is not related to sex or dosage. 
But is related to age which is statistically significant
In  our  study  compared  to  older  age  group,  younger  age  is  more 
susceptible to hyperuricemia. In patients less than 40 years, the incidence is 
80 to 100% and in patients more than 40 years old it was only 10 to 50%.
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APPENDIX
PROFORMA
Serum uric  acid estimation in  patients  receiving regimen containing 
Pyrazinamide
Name : Age  : Sex   :
Address : Occupation : Op No :
Income : Index No : Regimen :
Complaints : Duration :
Weight :
Past History
a. H/O prior antituberculosis treatment.
b. History of previous joint pain.
c. History of gout.
d. History of hypertension
e. History of renal insufficiency.
f. History of chronic intake of any medications.
g. History of alcohol intake / smoking
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General Examination
Systemic examination :
Respiratory system :
Cardiovascular system :
Central nervous system :
Abdomen :
Examination of Joints
1. Joint/Joints involved : Present / Absent
2. Pain : Present / Absent
3. Limitation of movement : Present / Absent
4. Tenderness : Present / Absent
5. Joint swelling : Present / Absent
6. Effusion and discolouration : Present / Absent
    of skin
Investigations
a. X-Ray Chest PA view – 0, 2nd month
b. Sputum smear for AFB – 0,2nd month
c. Urine for Albumin/Sugar/Deposit.
d. Mantoux
e. Pleural fluid analysis.
f. Serum Uric acid –
1. To estimate before treatment started.
2. To estimate every 15 days during intensive phase.
3. To estimate at the end of intensive phase.
g. Blood, TC, DC, ESR, Hb%
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MASTER CHART
S. No Name Age Sex Weight Regimen
Uric acid
Arthralgia
Before
treatment
After
treatment.
1 Perumayee 18 F 28 HREZ 1.2 8.1 1
2 Ramasamy 52 M 63 HREZ 2 5.4 2
3 Arumugam 63 F 60 HRZ 2.5 3.4 2
4 Chitra 54 F 61 HRZ 4.2 8 2
5 Ganapathy 19 M 35 HRZ 3.6 7 2
6 Sivanandi 53 M 64 HREZ 4.2 12.6 2
7 Valli 20 F 25 HRZ 3 6.5 2
8 Ramasamy 20 M 35 HREZ 2.8 2
9 Muthupillai 22 F 34 HRZ 4.4 7.1 2
10 Ayyanar 26 M 50 HRZ 2 5 2
11 Srinivasan 17 M 28 HREZ 1.2 7.6 1
12 Muthu 48 F 64 HRZ 2 4.2 2
13 Kirupanandham 65 M 59 HRZ 3.7 7 2
14 Thangavelu 62 M 58 HREZ 5.1 7.1 1
15 P aramasamy 23 M 40 HRZ 5 6.6 2
16 Malaiyappan 45 M 51 HREZ 4.2 2
17 Thangam 32 M 50 HREZ 4.2 8.2 1
18 Petchiammmal 43 F 48 HREZ 2 9.7 2
19 Mookammal 33 F 42 HRZ 2.1 8 1
20 Andammel 26 F 42 HRZ 2.1 6.6 2
21 Vasanthi 18 F 28 HREZ 3.9 6.9 2
22 Chinnnaadaikkan 44 M 62 HRZ 5.1 2
23 Senthikani 26 F 32 HRZ 1.8 6.1 2
24 Rameshbabu 27 M 40 HRZ 4.8 9.1 2
25 Ramasamy 56 M 52 HREZ 3 4.4 2
26 Azhagu 22 M 45 HRZ 2.6 3.6 1
27 Ramar 14 M 25 HREZ 2.8 5.6 2
28 Mangaiyarkarasi 50 F 65 HREZ 4.9 2
29 Chinnammal 24 F 40 HRZ 4.4 6.7 2
30 Ganesan 57 M 65 HREZ 2.8 4.4 2
31 Karuppaiya 38 M 50 HREZ 1.8 4.8 1
32 Mayandi 39 M 48 HRZ 4.9 2
33 Kazhuvayee 48 F 64 HRZ 5.6 10.2 1
34 Muthu 50 M 58 HREZ 4.7 6.9 2
35 Ganga 20 F 35 HRZ 3.1 5.6 2
36 Azhagu 67 M 62 HREZ 2.5 7.2 2
37  Rakku 33 F 62 HRZ 5.1 2
38 Muthup andi 74 F 67 HRZ 1.6 2.8 2
39 Ramu 32 M 46 HREZ 3.1 6.4 2
40 Jeyaprakash 31 M 45 HREZ 2.8 6.4 2
41 Nagaraj 30 M 45 HREZ 4 6.6 2
42 Saravansalen 30 M 45 HREZ 3.8 7.4 2
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S. No Name Age Sex Weight Regimen
Uric acid
Arthralgia
Before
treatment
After
treatment.
43 Arunkumar 48 M 60 HRZ 1.8 8 2
44 Manickam 62 M 65 HREZ 2.6 2
45 Chellakannu 44 M 48 HRZ 1.9 7.8 1
46 Muthu 53 F 48 HREZ 3 6 2
47 Manimegalai 37 F 45 HREZ 3.2 4.8 2
48 Sonaimuthu 49 M 52 HRZ 4.2 4.8 2
49 Vanitha 55 F 62 HREZ 2.9 2
50 Kanthan 16 M 34 HRZ 3.8 5.2 2
51 Govindhan 58 M 60 HRZ 4 9.6 2
52 Ravichandran 25 M 38 HREZ 4.2 6.6 2
53 Muthupechi 57 F 62 HREZ 2.3 2
54 Rajendran 33 M 45 HREZ 3.8 9.4 1
55 Paulpandy 44 M 45 HRZ 2.7 4.7 2
56 Kalimuthu 58 M 58 HRZ 2 5.3 2
57 Paunraj 41 M 50 HREZ 4.1 7.2 2
58 Sekar 50 M 62 HREZ 5.4 2
59 Ramesh  33 M 52 HRZ 2 4 2
60 Perumal 48 M 52 HREZ 5.1 7.7 2
61 Kazhuvayee 55 F 50 HRZ 1 3.1 2
62 Muniyan 65 M 60 HRZ 2.2 4.7 1
63 Ganesh 40 M 55 HRZ 2.3 3.7 2
64 Selvi 40 F 42 HREZ 2.6 7.4 2
65 Avudaiachi 50 F 45 HRZ 2.5 2
66 Muthu 53 M 55 HRZ 2.3 4.6 2
67 Vairavan 62 M 65 HRZ 3 2.3 2
68 Alagammel 62 F 64 HREZ 3.1 7.4 2
69 Sumathi 40 F 40 HREZ 4.1 6.5 2
70 Thangaraj 28 M 38 HRZ 5.5 2
71 Murugan 61 M 60 HRZ 3 4 2
72 Paulkanna 64 M 60 HREZ 2 4.5 2
73 Seeniammal 70 F 58 HREZ 2.8 6 2
74 Sivagami 20 F 28 HREZ 2.2 6.8 1
75 Raju 32 M 48 HREZ 1.7 7.3 2
76 Chinnaiya 38 M 58 HRZ 1.2 4.1 2
77 Shenbagam 26 F 35 HREZ 4 4.4 1
78 Geetha 58 F 58 HREZ 5.6 2
79 Kaunammal 56 F 53 HREZ 3.2 6.7 2
80 Paramasivam 55 M 62 HREZ 2.2 6.2 2
81 Madhivanan 23 M 30 HREZ 2.4 8.4 2
82 Malliga 45 F 40 HREZ 2 4.7 2
83 Govindammal 62 F 62 HREZ 2.9 2
84 Subramani 24 M 40 HREZ 2.6 7.6 2
85 Kangammal 25 F 40 HREZ 1.2 4 1
86 Aadeeswari 38 F 58 HRZ 1 4.7 2
87 Perumal 46 M 64 HREZ 3.9 2
88 Sureshkumar 32 M 48 HREZ 3 6.8 2
89 Suresh  49 M 60 HREZ 4 5.4 2
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S. No Name Age Sex Weight Regimen
Uric acid
Arthralgia
Before
treatment
After
treatment.
90 Mohammed Meeran 63 M 58 HREZ 3 5.4 2
91 Angulakshmi 68 F 28 HRZ 1.5 8.2 2
92 Thirumugam 45 M 56 HREZ 2.2 5.9 2
93 Kannan 45 M 62 HRZ 2.7 2
94 Venkateshan 25 M 34 HREZ 2.8 8.6 2
95 Subbiah 32 M 48 HRZ 4.1 7.1 2
96 Mylathal 40 F 48 HREZ 5.4 4.4 1
97 Gandhimathi 26 F 40 HREZ 3.3 6.9 2
98 Veerachamy 29 M 48 HRZ 5.7 2
99 Mohan 42 M 60 HRZ 4.1 6.4 1
100 Pasumpon 29 F 42 HREZ 2.4 6.9 1
101 Sumathy 25 F 33 HRZ 2.1 2
102 Dhanalakshmi 38 F 45 HREZ 2.1 6.5 1
103 Anwar 72 M 62 HRZ 2.3 5.4 2
104 Subramanian 14 M 32 HRZ 2.8 6.4 2
105 Chinamuthu 65 M 60 HRZ 2.2 4.7 1
106 Mariappan 49 M 60 HREZ 4 5.4 2
107 Pandiyan 61 M 56 HREZ 5.1 7.1 1
108 Abdullah 31 M 41 HREZ 4 6.6 2
109 Murugan 53 M 53 HREZ 5.1 7.7 2
110 chitra 40 F 42 HREZ 2.6 7.4 2
111 devi 52 F 60 HREZ 2.3
112 Raman 24 M 47 HRZ 2.6 3.6 1
113 Sundari 25 F 33 HRZ 2.1
114 Seeniappan 57 M 62 HRZ 4 9.6 2
115 Sundararaj 25 M 38 HREZ 4.2 6.6 2
116 Mariyamma 50 F 65 HREZ 4.9
117 Mariappan 45 M 51 HREZ 4.2
118 Pandiyan 26 M 50 HRZ 2 5 2
119 Abdullah 30 M 45 HREZ 3.8 7.4 2
120 Murugan 31 M 49 HRZ 5.7
121 Sivakumar 23 M 30 HREZ 2.4 8.4 2
122 Raji 54 F 61 HRZ 4.2 8 2
123 Stephen 20 M 42 HRZ 5 6.6 2
124 Chellamma 58 F 58 HREZ 5.6
125 Veeranan 42 M 57 HRZ 2.3 3.7 2
126 Rani 20 F 29 HREZ 2.2 6.8 1
127 Kuppan 30 M 47 HREZ 3.8 9.4 1
128 Mangai 19 F 36 HRZ 3.1 5.6 2
129 Rajendran 41 M 50 HREZ 4.1 7.2 2
130 Kalavathy 48 F 64 HRZ 5.6 10.2 1
131 Ashok 44 M 62 HRZ 5.1
132 Rangasamy 65 M 59 HRZ 3.7 7 2
133 Amudha 26 F 42 HRZ 2.1 6.6 2
134 Paneer Selvam 16 M 34 HRZ 3.8 5.2 2
135 Perumal 62 M 65 HRZ 3 2.3 2
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After
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136 Sivagami 38 F 58 HRZ 1 4.7 2
137 Shenbagam 26 F 40 HREZ 3.3 6.9 2
138 Geetha 49 F 62 HRZ 2 4.2 2
139 Chinnapayan 66 M 60 HREZ 2.5 7.2 2
140 Arumugam 58 M 60 HRZ 2.2 4.7 1
141 Manikandan 24 M 39 HRZ 5.5
142 Karthikeyan 47 M 61 HRZ 1.8 8 2
143 Kumar 63 M 57 HRZ 3.7 7 2
144 Kangammal 40 F 48 HREZ 5.4 4.4 1
145 Aadeeswari 26 F 35 HREZ 4 4.4 1
146 Jeyaraj 50 M 62 HREZ 5.4
147 Mylathal 53 F 48 HREZ 3 6 2
148 Muthusamy 14 M 25 HREZ 2.8 5.6 2
149 Kayakudiyan 17 M 28 HREZ 1.2 7.6 1
150 Karthik 30 M 45 HREZ 4 6.6 2
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